Story perspectives

Promising mRNA Vaccines Boost Survival in Pancreatic Cancer Trial

4/19/2026

Summary

Story summary

Donna Gustafson, diagnosed with Stage 2 pancreatic cancer in 2019, participated in a clinical trial of personalized mRNA vaccines.
Dr. Vinod Balachandran led the trial and noted Gustafson was among eight patients who generated a strong immune response.
The immune response could potentially extend the participants' survival.
A separate development, daraxonrasib, showed promising results in a Phase 3 trial, significantly increasing survival rates for advanced pancreatic cancer.

1 of 1

Story summary

Donna Gustafson, diagnosed with Stage 2 pancreatic cancer in 2019, participated in a clinical trial of personalized mRNA vaccines.
Dr. Vinod Balachandran led the trial and noted Gustafson was among eight patients who generated a strong immune response.
The immune response could potentially extend the participants' survival.
A separate development, daraxonrasib, showed promising results in a Phase 3 trial, significantly increasing survival rates for advanced pancreatic cancer.